Defined Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$526K Buy
2,011
+39
+2% +$10K 0.27% 79
2026
Q2
$496K Buy
1,972
+92
+5% +$19.8K 0.26% 83
2026
Q1
$409K Sell
1,880
-44
-2% -$9.8K 0.24% 82
2025
Q4
$440K Buy
1,924
+24
+1% +$5.47K 0.25% 79
2025
Q3
$440K Buy
1,900
+59
+3% +$12K 0.26% 80
2025
Q2
$342K Buy
1,841
+367
+25% +$68.2K 0.21% 90
2025
Q1
$309K Sell
1,474
-97
-6% -$18.9K 0.21% 92
2024
Q4
$279K Buy
1,571
+31
+2% +$5.7K 0.18% 98
2024
Q3
$304K Sell
1,540
-30
-2% -$5.6K 0.2% 97
2024
Q2
$269K Buy
1,570
+28
+2% +$4.64K 0.19% 98
2024
Q1
$281K Buy
1,542
+30
+2% +$5.17K 0.2% 95
2023
Q4
$234K Sell
1,512
-16
-1% -$2.33K 0.18% 96
2023
Q3
$228K Buy
+1,528
New +$224K 0.19% 95
2023
Q2
– Sell
-1,467
Closed -$234K – 99
2023
Q1
$234K Hold
1,467
– – 0.22% 93
2022
Q4
$237K Buy
+1,467
New +$225K 0.22% 97
2022
Q3
– Sell
-1,467
Closed -$225K – 92
2022
Q2
$225K Hold
1,467
– – 0.23% 86
2022
Q1
$238K Buy
+1,467
New +$213K 0.21% 90
2021
Q1
– Sell
-1,399
Closed -$150K – 96
2020
Q4
$150K Buy
+1,399
New +$134K 0.15% 100

Other funds holding ABBV

Defined Wealth Management's ABBV Position: Q3 2026 in Review

Defined Wealth Management increased its AbbVie (ABBV) stake by 2% in Q3 2026, buying an estimated $10K and bringing the position to 2,011 shares worth $526K. The position accounts for 0.27% of the portfolio, ranked #79.

Defined Wealth Management first reported a position in ABBV in Q4 2020 and has held it in 18 quarters since. 970 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Defined Wealth Management held 2,011 shares of AbbVie worth $526K as of Q3 2026.
  • Defined Wealth Management bought 39 AbbVie shares in Q3 2026, an estimated $10K.
  • AbbVie made up 0.27% of Defined Wealth Management's portfolio in Q3 2026, its #79 holding.
  • Defined Wealth Management first reported a position in AbbVie in Q4 2020 and has held it in 18 quarters since.
  • 970 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Defined Wealth Management's 13F filing for Q3 2026, filed 19 Oct 2026.